title: Tailoring adjuvant treatments for the individual patient with luminal breast cancer.
abstract: Estrogen Receptor-positive/HER-2 negative breast cancers represent a heterogeneous group of tumors. Luminal A and B tumor subtypes can be identified through immunohistochemical assessment of estrogen and progesterone receptor, Ki-67 and HER-2 status. Patients with high levels of expression of steroid hormone receptors and low proliferation (Luminal A) are commonly cured with endocrine therapy alone. Patients with doubtful endocrine responsiveness or with high proliferation index (Luminal B/Her-negative) require the addition of chemotherapy to the best endocrine therapy. Controversies still exist on the identification of those patients who do not benefit from chemotherapy. Tailored adjuvant treatments should be considered in the therapeutic algorithm of patients with luminal tumors.
authors.affiliation: Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy. elisabetta.munzone@ieo.it
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Munzone
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Curigliano
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans
chemical_list: D018931:Antineoplastic Agents, Hormonal
keywords: Adjuvant therapy; Breast cancer; Endocrine therapy; Gene assay; Luminal A; Luminal B